• Home
  • Browse
    • Current Issue
    • By Issue
    • By Author
    • By Subject
    • Author Index
    • Keyword Index
  • Journal Info
    • About Journal
    • Aims and Scope
    • Editorial Board
    • Publication Ethics
    • Peer Review Process
  • Guide for Authors
  • Submit Manuscript
  • Contact Us
 
  • Login
  • Register
Home Articles List Article Information
  • Save Records
  • |
  • Printable Version
  • |
  • Recommend
  • |
  • How to cite Export to
    RIS EndNote BibTeX APA MLA Harvard Vancouver
  • |
  • Share Share
    CiteULike Mendeley Facebook Google LinkedIn Twitter
Suez Canal University Medical Journal
arrow Articles in Press
arrow Current Issue
Journal Archive
Volume Volume 28 (2025)
Volume Volume 27 (2024)
Volume Volume 26 (2023)
Volume Volume 25 (2022)
Volume Volume 24 (2021)
Volume Volume 23 (2020)
Volume Volume 22 (2019)
Volume Volume 21 (2018)
Volume Volume 20 (2017)
Volume Volume 19 (2016)
Volume Volume 18 (2015)
Volume Volume 17 (2014)
Volume Volume 16 (2013)
Volume Volume 15 (2012)
Volume Volume 14 (2011)
Issue Issue 1
Volume Volume 13 (2010)
El-Ellisy, D., Ewais, M., El-Awady, E., Tawfik, G. (2011). Effect of Alfacalcidol on Anemia in Renal Failure Patients. Suez Canal University Medical Journal, 14(1), 11-15. doi: 10.21608/scumj.2011.56014
Dalal El-Ellisy; Mohamed M Ewais; El-Sayed E El-Awady; Gamal A Tawfik. "Effect of Alfacalcidol on Anemia in Renal Failure Patients". Suez Canal University Medical Journal, 14, 1, 2011, 11-15. doi: 10.21608/scumj.2011.56014
El-Ellisy, D., Ewais, M., El-Awady, E., Tawfik, G. (2011). 'Effect of Alfacalcidol on Anemia in Renal Failure Patients', Suez Canal University Medical Journal, 14(1), pp. 11-15. doi: 10.21608/scumj.2011.56014
El-Ellisy, D., Ewais, M., El-Awady, E., Tawfik, G. Effect of Alfacalcidol on Anemia in Renal Failure Patients. Suez Canal University Medical Journal, 2011; 14(1): 11-15. doi: 10.21608/scumj.2011.56014

Effect of Alfacalcidol on Anemia in Renal Failure Patients

Article 3, Volume 14, Issue 1, March 2011, Page 11-15  XML PDF (118.97 K)
Document Type: Original Article
DOI: 10.21608/scumj.2011.56014
View on SCiNiTO View on SCiNiTO
Authors
Dalal El-Ellisy* 1; Mohamed M Ewais2; El-Sayed E El-Awady1; Gamal A Tawfik3
1Department of Pharmacology & Toxicology, Faculty of Pharmacy, Suez Canal University, Egypt.
2Department of Pharmacology & Toxicology, Faculty of Medicine, Suez Canal University, Egypt.
3Department of Internal Medicine, Faculty of Medicine, Suez Canal University, Egypt
Abstract
Background: Anemia is a major feature of chronic kidney disease (CKD). Additionally, secondary hyperparathyroidism (SHPT) has been associated with anemia in uremic patients. Administration of active vitamin D metabolites like alfacalcidol is established for PTH suppression and may also play a role in hematopoiesis. Aim:To investigate the effect of alfacalcidol on anemia and SHPT with end stage renal failure patients underwent hemodialysis. Subjects and Methods: In the present study 17 anemic patients over 15years, with serum level of PTH greater than 500pg/ml. The study was carried out by means of data collection and analysis of serum parathyroid hormone (PTH) and hemoglobin (Hb) levels in these patients. Results: Low serum PTH levels were detected in uremic patients treated with alfacalcidol. Also, in these patients, Hb levels increased. Serum PTH and Hb levels were inversely correlated. Conclusions: High-dose alfacalcidol can decrease serum PTH levels and elevate Hb level in uremic patients showing considerable resistance to Epoetin.
 
 
Keywords
Anemia; PTH; alfacalcidol; ESRD; uremic patients; SHPT
Statistics
Article View: 246
PDF Download: 554
Home | Glossary | News | Aims and Scope | Sitemap
Top Top

Journal Management System. Designed by NotionWave.